Back

Second multistate outbreak of tuberculosis caused by a bone allograft product

Schildknecht, K. R.; Williams, P. M.; Schwartz, N. G.; Haddad, M. B.; Stewart, R. J.; Annambhotla, P.; Basavaraju, S. V.; Nabity, S. A.; Keh, C. E.; Calvet, H. M.; Zahn, M. M.; Beltran, R.; Cortez, A.; Lomeli, A.; Percak, J. M.; Gooze, L. L.; Coloma, M.; Shaw, T.; Davidson, P. J.; Smith, S. R.; Dickson, R. P.; Kaul, D. R.; Gonzalez, A. R.; Rodriguez, G.; Decimo, A.; Sanchez, A.; Armitige, L. Y.; Stapleton, J.; Lacassagne, M.; Brown, C.; Zheng, C.; Ali, J.; Wolfe, A. W.; Young, L. R.; Ariail, K.; Behm, H.; Jordan, H. T.; Spencer, M.; Nilsen, D. M.; Goradia, R.; Montoya Denison, B.; Burgos, M.;

2026-05-06 transplantation
10.64898/2026.04.29.26351868 medRxiv
Show abstract

Tuberculosis screening is not mandatory for prospective tissue donors. In 2021 and 2023, two different bone allograft products caused nationwide tuberculosis outbreaks. We assessed the morbidity and mortality of the second outbreak and reviewed donor and tissue screening to identify deficiencies. Thirty-six people residing in nine states received the product during spinal and dental procedures. Twenty-seven recipients had tuberculosis infection, 11 had microbiologic or imaging evidence of tuberculosis disease, and two died from tuberculosis within 12 months of outbreak detection. Another recipient died from tuberculosis nearly 3 years after product implantation. The bone donor died of pneumonia and septic shock. Polymerase chain reaction testing of the product before and after distribution did not detect Mycobacterium tuberculosis. Mycobacterial culture was not performed until after outbreak detection, when M. tuberculosis was isolated from 2 of 6 unused product units. This outbreak demonstrates persistent gaps in tissue transplant safety. Appropriate selection of donors and mycobacterial culture of donated tissues could reduce but not eliminate the risk of M. tuberculosis transmission. Therefore, it is important that clinicians monitor tissue recipients and promptly report adverse events to tissue establishments and health authorities.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Microbiology Spectrum
469 papers in training set
Top 0.2%
17.1%
2
JAMA Network Open
130 papers in training set
Top 0.1%
13.1%
3
American Journal of Transplantation
18 papers in training set
Top 0.1%
11.0%
4
Annals of Internal Medicine
28 papers in training set
Top 0.1%
10.1%
50% of probability mass above
5
Transplantation
13 papers in training set
Top 0.1%
9.2%
6
PLOS ONE
5266 papers in training set
Top 27%
5.7%
7
Science Translational Medicine
127 papers in training set
Top 0.4%
4.2%
8
npj Regenerative Medicine
24 papers in training set
Top 0.2%
2.7%
9
Frontiers in Public Health
148 papers in training set
Top 2%
2.5%
10
Frontiers in Medicine
120 papers in training set
Top 2%
1.8%
11
Journal of Immunological Methods
24 papers in training set
Top 0.2%
1.8%
12
eLife
5828 papers in training set
Top 48%
1.7%
13
Nature Communications
5641 papers in training set
Top 48%
1.4%
14
The Journal of Infectious Diseases
202 papers in training set
Top 3%
1.4%
15
The Journal of Heart and Lung Transplantation
11 papers in training set
Top 0.3%
1.2%
16
Frontiers in Immunology
638 papers in training set
Top 7%
1.2%
17
BMJ Open
601 papers in training set
Top 12%
0.9%
18
Clinical Journal of the American Society of Nephrology
10 papers in training set
Top 0.2%
0.6%
19
Biomaterials
84 papers in training set
Top 2%
0.6%
20
Frontiers in Bioengineering and Biotechnology
98 papers in training set
Top 3%
0.6%
21
Transfusion
21 papers in training set
Top 0.2%
0.6%
22
STAR Protocols
18 papers in training set
Top 0.3%
0.5%
23
Annals of Biomedical Engineering
37 papers in training set
Top 1%
0.5%
24
Communications Medicine
113 papers in training set
Top 6%
0.5%
25
Antimicrobial Agents and Chemotherapy
187 papers in training set
Top 2%
0.5%
26
Blood
74 papers in training set
Top 1%
0.5%
27
Biomaterials Science
24 papers in training set
Top 0.8%
0.5%